Drug News

Zacks: Neutral On Merck; And Probably Right

March 17, 2011   ·   0 Comments

all , for much additional, and nuanced , detail: . . . .Merck is currently facing issues such as patent expirations of key drugs, EU pricing pressure, US health care reform, and pipeline setbacks. We believe the company will have to resort to
Moreover Technologies – Search results for… drugs – 30 of 1191 returned


Readers Comments (0)

You must be logged in to post a comment.